Compound useful for the treatment of degenerative and inflammatory diseases

Patent metadata

Field	Value
Publication number	US-9505754-B2
Application number	US-201414451127-A
Country	US
Kind code	B2
Filing date	Aug 4, 2014
Priority date	Jun 26, 2009
Publication date	Nov 29, 2016
Grant date	Nov 29, 2016

Abstract

A compound is disclosed that has a formula represented by the following:

This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.

First claim

What is claimed is:

1. A method for the treatment of an inflammatory condition selected from Crohn's disease and colitis, or a proliferative disease selected from psoriasis, said method comprising administering a therapeutically effective amount of a compound according to Formula I:

or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , comprising the administration of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of said compound, or a pharmaceutically acceptable salt thereof.

3. The method according to claim 1 , wherein the inflammatory condition is Crohn's disease.

4. The method according to claim 1 , wherein the inflammatory condition is colitis.

5. The method according to claim 1 , wherein the method is for the treatment of psoriasis.

6. The method according to claim 2 , wherein the inflammatory condition is Crohn's disease.

7. The method according to claim 2 , wherein the inflammatory condition is colitis.

8. The method according to claim 2 , wherein the method is for the treatment of psoriasis.

9. The method according to claim 1 , wherein said compound is administered in combination with a further therapeutic agent.

10. The method according to claim 2 , wherein said pharmaceutical composition is administered in combination with a further therapeutic agent.

11. The method according to claim 9 , wherein said further therapeutic agent is an agent for the treatment of Crohn's disease.

12. The method according to claim 9 , wherein said further therapeutic agent is an agent for the treatment of colitis.

13. The method according to claim 9 , wherein said further therapeutic agent is an agent for the treatment of psoriasis.

14. The method according to claim 10 , wherein said further therapeutic agent is an agent for the treatment of Crohn's disease.

15. The method according to claim 10 , wherein said further therapeutic agent is an agent for the treatment of colitis.

16. The method according to claim 10 , wherein said further therapeutic agent is an agent for the treatment of psoriasis.

17. The method according to claim 11 , wherein the further therapeutic agent is an agent selected from glucocorticoids, synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.

18. The method according to claim 17 , wherein the further therapeutic agent is selected from prednisone, budesonide, methotrexate, leflunomide, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporine, infliximab, adalimumab, rituximab, and abatacept.

19. The method according to claim 12 , wherein the further therapeutic agent is an agent selected from glucocorticoids, synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.

20. The method according to claim 19 , wherein the further therapeutic agent is selected from prednisone, budesonide, methotrexate, leflunomide, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporine, infliximab, adalimumab, rituximab, and abatacept.

21. The method according to claim 13 , wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D 3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.

22. The method according to claim 21 , wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and ustekinumab.

Assignees

• Menet Christel Jeanne Marie
• Blanc Javier
• Galapagos Nv

Inventors

• Menet Christel Jeanne Marie
• Blanc Javier

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title